KineMed pulls in $15M for Lou Gehrig's disease

August 3, 2007 | David P. Hamilton
View Comments

KineMed, an Emeryville, Calif., biotech developing a new treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease, raised $15 million in a convertible note offering. See our story at VentureBeat Life Sciences here.

Next Story:
Previous Story:

Print
Email
Twitter
Facebook
Google Buzz
LinkedIn
Digg
StumbleUpon
Reddit
Delicious
Google
More...
Photo of David P. Hamilton

About the Author,

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.

blog comments powered by Disqus